See more : Futuris Company (FTRS) Income Statement Analysis – Financial Results
Complete financial analysis of Lannett Company, Inc. (LCI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lannett Company, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- TSI Holdings Co.,Ltd. (TSIHF) Income Statement Analysis – Financial Results
- Planetree International Development Limited (0613.HK) Income Statement Analysis – Financial Results
- Adcock Ingram Holdings Limited (AIHLF) Income Statement Analysis – Financial Results
- NR Instant Produce Public Company Limited (NRF.BK) Income Statement Analysis – Financial Results
- Lithium Americas (Argentina) Corp. (LAAC) Income Statement Analysis – Financial Results
Lannett Company, Inc. (LCI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.lannett.com
About Lannett Company, Inc.
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 340.58M | 478.78M | 545.74M | 655.41M | 684.56M | 637.34M | 566.09M | 406.84M | 273.77M | 151.05M | 122.99M | 106.84M | 125.18M | 119.00M | 72.40M | 82.58M | 64.06M | 44.90M | 63.78M | 42.49M | 25.13M | 12.09M | 11.55M | 10.60M | 9.46M | 3.80M | 3.82M |
| Cost of Revenue | 307.41M | 403.19M | 380.52M | 411.80M | 395.86M | 332.13M | 256.00M | 100.48M | 119.36M | 93.63M | 84.04M | 83.52M | 83.84M | 73.76M | 54.08M | 57.39M | 33.90M | 31.42M | 26.86M | 16.26M | 8.45M | 6.53M | 7.89M | 6.60M | 6.12M | 2.64M | 1.87M |
| Gross Profit | 33.17M | 75.59M | 165.22M | 243.61M | 288.71M | 305.21M | 310.09M | 306.36M | 154.41M | 57.42M | 38.95M | 23.32M | 41.34M | 45.24M | 18.32M | 25.18M | 30.16M | 13.48M | 36.92M | 26.23M | 16.67M | 5.56M | 3.66M | 4.00M | 3.34M | 1.16M | 1.95M |
| Gross Profit Ratio | 9.74% | 15.79% | 30.27% | 37.17% | 42.17% | 47.89% | 54.78% | 75.30% | 56.40% | 38.01% | 31.67% | 21.83% | 33.02% | 38.02% | 25.31% | 30.50% | 47.08% | 30.03% | 57.89% | 61.73% | 66.36% | 45.95% | 31.70% | 37.74% | 35.33% | 30.64% | 51.10% |
| Research & Development | 22.36M | 24.17M | 29.98M | 38.81M | 29.20M | 42.07M | 45.05M | 30.34M | 27.71M | 16.25M | 11.84M | 8.59M | 11.25M | 8.43M | 5.17M | 7.46M | 8.10M | 6.27M | 5.90M | 2.58M | 1.75M | 1.40M | 730.65K | 900.00K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 82.20M | 73.48M | 0.00 | 49.53M | 38.61M | 22.41M | 20.19M | 15.91M | 17.38M | 26.06M | 16.79M | 14.13M | 11.80M | 9.19M | 8.86M | 4.34M | 3.30M | 2.01M | 1.36M | 1.20M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 81.02M | 68.08M | 79.47M | 87.65M | 82.20M | 73.48M | 68.33M | 49.53M | 38.61M | 22.41M | 20.19M | 15.91M | 17.38M | 26.06M | 16.79M | 14.13M | 11.80M | 9.19M | 8.86M | 4.34M | 3.30M | 2.01M | 1.36M | 1.20M | 0.00 | 0.00 | 0.00 |
| Other Expenses | 178.00K | -1.66M | -840.00K | -2.02M | 47.62M | 99.22M | 68.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -230.57K | 9.55M | 1.80M | 51.66M | 1.33M | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 1.66M | 1.24M | 1.26M |
| Operating Expenses | 103.39M | 92.25M | 109.45M | 126.46M | 111.39M | 115.55M | 113.38M | 79.87M | 66.32M | 38.66M | 32.04M | 24.50M | 28.63M | 34.49M | 21.73M | 31.15M | 21.71M | 67.12M | 16.09M | 6.91M | 5.05M | 3.42M | 2.09M | 2.20M | 1.66M | 1.24M | 1.26M |
| Cost & Expenses | 410.80M | 495.44M | 489.97M | 538.25M | 507.25M | 447.68M | 369.38M | 180.35M | 185.68M | 132.30M | 116.08M | 108.01M | 112.46M | 108.24M | 75.81M | 88.54M | 55.61M | 98.54M | 42.95M | 23.17M | 13.50M | 9.95M | 9.98M | 8.80M | 7.78M | 3.87M | 3.13M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 425.00K | 295.00K | 116.00K | 142.00K | 90.99K | 62.33K | 209.19K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 57.98M | 53.83M | 66.85M | 84.62M | 85.63M | 89.42M | 65.94M | 207.00K | 130.00K | 251.00K | 273.00K | 214.52K | 275.87K | 321.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 178.00K | -1.66M | 56.31M | 55.59M | 55.12M | 55.34M | 33.43M | 5.58M | 5.98M | 6.20M | 5.74M | 4.98M | 4.89M | 5.10M | 5.23M | 4.47M | 3.97M | 6.97M | 2.51M | 982.19K | 789.30K | 767.05K | 678.63K | 600.00K | 369.37K | 206.69K | 204.27K |
| EBITDA | -176.27M | -18.32M | 54.94M | 115.14M | 191.84M | 145.28M | 161.47M | 233.14M | 96.07M | 27.07M | 12.56M | 4.45M | 17.80M | 16.05M | -464.71K | -1.46M | 12.50M | -46.85M | 23.32M | 19.98M | 11.97M | 3.60M | 1.56M | 1.50M | 1.25M | -582.65K | 341.33K |
| EBITDA Ratio | -20.57% | -3.83% | 10.07% | 17.57% | 28.02% | 22.79% | 28.52% | 57.31% | 35.09% | 17.92% | 10.21% | 4.17% | 14.22% | 13.48% | -0.64% | -1.76% | 19.51% | -104.35% | 36.56% | 47.04% | 47.64% | 29.81% | 13.53% | 14.15% | 13.15% | -15.33% | 8.94% |
| Operating Income | -70.22M | -16.66M | -1.37M | 59.54M | 129.70M | 86.45M | 130.76M | 226.49M | 88.09M | 18.76M | 6.91M | -994.95K | 13.03M | 10.78M | -5.43M | -5.96M | 8.45M | -53.64M | 20.83M | 19.32M | 11.63M | 2.14M | 1.58M | 1.80M | 1.68M | -72.12K | 691.34K |
| Operating Income Ratio | -20.62% | -3.48% | -0.25% | 9.08% | 18.95% | 13.56% | 23.10% | 55.67% | 32.18% | 12.42% | 5.62% | -0.93% | 10.41% | 9.06% | -7.50% | -7.22% | 13.20% | -119.46% | 32.66% | 45.46% | 46.27% | 17.69% | 13.63% | 16.98% | 17.75% | -1.90% | 18.10% |
| Total Other Income/Expenses | -163.71M | -286.19M | -47.25M | -405.79M | -78.60M | -85.90M | -68.58M | 935.00K | 1.93M | 1.93M | -292.00K | 293.58K | -208.95K | -112.56K | -213.23K | 43.33K | 76.18K | -185.84K | -21.20K | -314.60K | -446.22K | 698.11K | -690.26K | -900.00K | -804.32K | -78.76K | -554.27K |
| Income Before Tax | -233.92M | -302.85M | -48.63M | -346.25M | 51.09M | 550.00K | 62.18M | 227.42M | 90.02M | 20.69M | 6.62M | -701.37K | 12.82M | 10.67M | -5.64M | -5.92M | 8.53M | -53.83M | 20.81M | 19.00M | 11.18M | 2.84M | 884.77K | 900.00K | 875.72K | -150.88K | 137.07K |
| Income Before Tax Ratio | -68.68% | -63.25% | -8.91% | -52.83% | 7.46% | 0.09% | 10.98% | 55.90% | 32.88% | 13.69% | 5.38% | -0.66% | 10.24% | 8.96% | -7.79% | -7.17% | 13.32% | -119.87% | 32.63% | 44.72% | 44.50% | 23.47% | 7.66% | 8.49% | 9.25% | -3.97% | 3.59% |
| Income Tax Expense | -2.30M | 60.63M | -15.26M | -74.14M | 22.40M | 1.10M | 17.32M | 77.43M | 32.86M | 7.30M | 2.60M | -461.57K | 4.81M | 4.09M | -3.38M | 1.01M | 3.56M | -21.05M | 7.59M | 7.33M | 3.98M | 1.01M | -465.33K | -400.00K | -150.00K | -78.76K | -554.27K |
| Net Income | -231.62M | -363.48M | -33.37M | -272.11M | 28.69M | -581.00K | 44.78M | 149.92M | 57.10M | 13.32M | 3.95M | -276.90K | 7.82M | 6.53M | -2.32M | -6.93M | 4.97M | -32.78M | 13.22M | 11.67M | 7.20M | 1.83M | 1.35M | 1.30M | 1.03M | -789.34K | 137.07K |
| Net Income Ratio | -68.01% | -75.92% | -6.11% | -41.52% | 4.19% | -0.09% | 7.91% | 36.85% | 20.86% | 8.82% | 3.21% | -0.26% | 6.25% | 5.49% | -3.20% | -8.39% | 7.76% | -73.00% | 20.72% | 27.46% | 28.64% | 15.13% | 11.69% | 12.26% | 10.84% | -20.77% | 3.59% |
| EPS | -22.96 | -36.91 | -3.46 | -28.81 | 0.19 | 0.00 | 0.31 | 1.05 | 0.42 | 0.12 | 0.03 | 0.00 | 0.08 | 0.07 | -0.02 | -0.07 | 0.05 | -0.34 | 0.16 | 0.15 | 0.09 | 0.02 | 0.02 | 0.04 | 0.03 | -0.03 | 0.00 |
| EPS Diluted | -22.96 | -36.91 | -3.46 | -28.81 | 0.19 | 0.00 | 0.30 | 1.01 | 0.41 | 0.12 | 0.03 | 0.00 | 0.08 | 0.07 | -0.02 | -0.07 | 0.05 | -0.34 | 0.16 | 0.15 | 0.09 | 0.02 | 0.02 | 0.04 | 0.03 | -0.03 | 0.00 |
| Weighted Avg Shares Out | 10.09M | 9.85M | 9.65M | 9.44M | 152.65M | 147.25M | 145.77M | 143.31M | 134.65M | 113.87M | 113.05M | 107.03M | 98.98M | 97.79M | 96.91M | 95.57M | 94.65M | 96.41M | 83.91M | 80.46M | 79.96M | 91.50M | 79.24M | 31.20M | 30.77M | 31.24M | 31.24M |
| Weighted Avg Shares Out (Dil) | 10.09M | 9.85M | 9.65M | 9.44M | 152.65M | 147.25M | 149.56M | 148.51M | 140.77M | 115.77M | 113.63M | 107.03M | 100.80M | 98.35M | 96.91M | 95.57M | 94.65M | 96.41M | 83.91M | 80.46M | 79.96M | 91.50M | 79.24M | 31.20M | 30.77M | 31.24M | 79.24M |
Lannett To Report Fiscal 2021 Third-Quarter Financial Results, Host Conference Call On Wednesday, May 5
PHILADELPHIA, April 28, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 third quarter on Wednesday, May 5, 2021, after the market closes. Lannett management will host a conference call...
Lannett Announces Closing Of $350 Million Senior Secured Notes And $190 Million Second Lien Senior Secured Loan Facility
PHILADELPHIA, April 22, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the closing of the $350 million aggregate principal amount of 7.750% senior secured notes due 2026 (the "Notes") in a private placement to qualified institutional buyers pursuant to...
Lannett Announces Pricing Of $350 Million Senior Secured Notes Due 2026
PHILADELPHIA, April 9, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) (the "Company" or "Lannett") today announced the pricing of the $350 million aggregate principal amount of 7.75% senior secured notes due 2026 (the "Notes") in a private placement to...
Lannett Announces Offering Of $350 Million Senior Secured Notes Due 2026
PHILADELPHIA, April 6, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) (the "Company") today announced that it intends to offer, subject to market conditions and other factors, $350 million aggregate principal amount of senior secured notes due 2026 (the "Notes") in...
Lannett Submits ANDA For Generic ADVAIR DISKUS®
PHILADELPHIA, April 1, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Abbreviated New Drug Application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the U.S. Food and...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lannett Company, Inc. - LCI
New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Lannett Company, Inc. ("Lannett" or the "Company") (NYSE: LCI). Such investors are advised to contact Robert S. Willoughby at [email protected]...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lannett Company, Inc. - LCI
NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lannett Company, Inc. ("Lannett" or the "Company") (NYSE: LCI). Such investors are advised to contact Robert S.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lannett Company, Inc. - LCI
New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Lannett Company, Inc. ("Lannett" or the "Company") (NYSE: LCI). Such investors are advised to contact Robert S. Willoughby at [email protected]...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lannett Company, Inc. - LCI
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lannett Company, Inc. ("Lannett" or the "Company") (NYSE: LCI). Such investors are advised to contact Robert S.
Lannett Development Of Biosimilar Insulin Glargine Product Continues To Advance
PHILADELPHIA, March 10, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it recently received feedback from the U.S. Food and Drug Administration (FDA) regarding biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners...
Source: https://incomestatements.info
Category: Stock Reports